Pathway to Cures

Professor of Pediatrics at Nationwide Children's Hospital/Ohio State University, Director of Pediatric Hematology, and Chair of NBDF's MASAC. She is Vice-President of the World Federation of Hemophilia, USA, and an NBDF board member.

Senior Vice President of Advancement for NBDF, responsible for donor fundraising for P2C and leading national development strategy and stakeholder relations. She has over 20 years of experience in nonprofit fundraising and management.

Andrew is listed as a chair on the P2C Investment Committee; no further biography is provided on the page.

Brennan is listed as a member of the P2C Investment Committee; no further biography is provided on the page.

Founder and Managing Partner of Agent Capital, overseeing portfolio management, new investments and operations. Previously Managing Partner of Baxter Ventures and Baxalta Ventures and a Partner at Quaker Partners; holds a PhD in biochemistry and an MBA from Wharton.

Hematologist and researcher serving as Adjunct Professor at UNC Chapel Hill and P2C Board Vice Chair & Secretary. He previously served as EVP for Research and Chief Scientific Officer of the Versiti Blood Research Institute.

Independent consultant and entrepreneur-in-residence at Third Rock Ventures, serving on WFH and NBDF advisory bodies. He retired from Biogen as SVP of Hematology, Cell and Gene Therapies and has 30 years of biotech R&D experience.

Co-founder and Chief Scientific Officer at PointLoma BioSciences with a drug development track record in cell and gene therapy. She contributed to therapies at Editas Medicine, Biogen, and Bayer, with 45 publications and 21 US patents.

Visiting professor at Rockefeller University and board member of Incyte, CRISPR Therapeutics, and Virion Therapeutics. She co-founded Spark Therapeutics and is a pioneer in AAV-mediated gene therapy for hemophilia, and a member of the National Academies of Medicine and Sciences.

Entrepreneur in Residence and former President and CEO of NBDF, instrumental in creating Pathway to Cures. He previously held senior roles at Spark Therapeutics, Shire, and Baxalta, and founded the Hemophilia and Thrombophilia Center at Rush University Medical Center.

Chief Medical and Scientific Advisor and Chair of the P2C Scientific Advisory Group. A pediatric hematology leader and Professor of Clinical Pediatrics at Yale, he previously served as Chief Science Officer of ATHN and directed hemophilia centers at OHSU and the Mountain States Hemophilia Network.

CFO of P2C and Chief Business Officer of NBDF, overseeing finance, accounting, business development, and IT. A senior healthcare finance and operations executive, he holds a BA in Biology from Augustana College and an MBA from the University of Chicago Booth School of Business.

P2C board member and President and CEO of NBDF. Previously President and CEO of the Epilepsy Foundation, where he drove significant revenue growth. He holds a bachelor's degree from Bradley University and a master's in education from National Louis University.

Pharmaceutical industry strategist with 28 years of experience in medical affairs and an NBDF board director. She has held senior medical affairs roles at Astellas, Spark Therapeutics, Baxter/Baxalta/Shire, and Eisai, and holds a PhD in Pharmacology from Howard University.

Professor of Pediatrics and Pathology at the University of Michigan and Medical Director of its Pediatric Hemophilia and Coagulation Disorders Program. He directs a research lab on factor VIII and hemophilia A and has been involved in novel hemophilia therapeutics including gene therapy.

Independent consultant and Adjunct Associate Professor at Queen's University specializing in gene therapy. With over 25 years of R&D experience, she pioneered the first approved AAV-based gene therapy for hemophilia A and led key hematology research programs at BioMarin.